Table 2 Distribution of height z-scores of treated and untreated MPS II patients at baseline, year 1, and year 2 of follow up as classified in to age groups
All (n = 11) | Treated (n = 2) | Untreated (n = 9) | |
|---|---|---|---|
Group 1 | |||
Baseline | |||
Stunted (z < − 2) % | 1 9% | 1 50% | 0 |
Normal (z < − 1 to > + 2) % | 10 91% | 1 50% | 9 100% |
Tall (z > + 3) % | 0 | 0 | 0 |
Year 1 | |||
Stunted (z < − 2) % | 3 27.3% | 1 50% | 2 22.22% |
Normal (z < − 1 to > + 2) % | 8 72.7% | 1 50% | 7 77.8% |
Tall (z > + 3) % | 0 | 0 | 0 |
Year 2 | |||
Stunted (z < − 2) % | 3 27.3% | 1 50% | 2 22.22% |
Normal (z < − 1 to > + 2) % | 8 72.7% | 1 50% | 7 77.8% |
Tall (z > + 3) % | 0 | 0 | 0 |
Group 2 | |||
Baseline (n = 16; Treated = 1; Untreated = 15) | |||
Stunted (z < − 2) % | 11 68.75% | 1 | 10 66.67% |
Normal (z < − 1 to > + 2) % | 5 31.25% | 0 | 5 33.33% |
Tall (z > + 3) % | 0 | 0 | 0 |
Year 1 (n = 13; Treated = 1; Untreated = 12) | |||
Stunted (z < − 2) % | 10 77% | 1 | 9 75% |
Normal (z < − 1 to > + 2) % | 3 23% | 0 | 3 25% |
Tall (z > + 3) % | 0 | 0 | 0 |
Year 2 (n = 10; Treated = 0; Untreated = 10) | |||
Stunted (z < − 2) % | 7 70% | NA | 7 70% |
Normal (z < − 1 to > + 2) % | 3 30% | NA | 3 30% |
Tall (z > + 3) % | 0 | NA | 0 |
Group 3 | |||
Baseline (n = 13; Treated = 5; Untreated = 8) | |||
Stunted (z < − 2) % | 13 100% | 5 100% | 8 100% |
Normal (z < − 1 to > + 2) % | 0 | 0 | 0 |
Tall (z > + 3) % | 0 | 0 | 0 |
Year 1 (n = 11; Treated = 5; Untreated = 6) | |||
Stunted (z < − 2) % | 11 100% | 5 100% | 6 100% |
Normal (z < − 1 to > + 2) % | 0 | 0 | 0 |
Tall (z > + 3) % | 0 | 0 | 0 |
Year 2 (n = 7; Treated = 4; Untreated = 3) | |||
Stunted (z < − 2) % | 7 100% | 4 100% | 3 100% |
Normal (z < − 1 to > + 2) % | 0 | 0 | 0 |
Tall (z > + 3) % | 0 | 0 | 0 |